Israel - engelsk - Ministry of Health

sanofi israel ltd - zolpidem tartrate - film coated tablets - zolpidem tartrate 10 mg - zolpidem - zolpidem - indications are limited to treatment of severe sleep disorders in the following cases: - occasional insomnia - transient insomnia.

Israel - engelsk - Ministry of Health

sanofi israel ltd - spiramycin - film coated tablets - spiramycin 1.5 miu - spiramycin - respiratory tract infections, infections caused by clamydia, cryptosporidiosis pregnancy toxoplasmosis.

Israel - engelsk - Ministry of Health

sanofi - aventis israel ltd - enoxaparin sodium - solution for injection - enoxaparin sodium 150 mg/ml - enoxaparin - enoxaparin - clexane forte is indicated in adults for: • prophylaxis of venous thromboembolic disease in moderate and high risk surgical patients, in particular those undergoing orthopaedic or general surgery including cancer surgery. • prophylaxis of venous thromboembolic disease in medical patients with an acute illness (such as acute heart failure, respiratory insufficiency, severe infections or rheumatic diseases) and reduced mobility at increased risk of venous thromboembolism. • treatment of deep vein thrombosis (dvt) and pulmonary embolism (pe), excluding pe likely to require thrombolytic therapy or surgery. • prevention of thrombus formation in extra corporeal circulation during haemodialysis. • acute coronary syndrome: - treatment of unstable angina and non st-segment elevation myocardial infarction (nstemi), in combination with oral acetylsalicylic acid. - treatment of acute st-segment elevation myocardial infarction (stemi) including patients to be managed medically or with subsequent percutaneous coronary inte

Israel - engelsk - Ministry of Health

sanofi israel ltd - amiodarone hydrochloride - solution for injection - amiodarone hydrochloride 50 mg / 1 ml - amiodarone - amiodarone - treatment should be initiated and normally monitored only under hospital or specialist supervision. amiodacore injection is indicated for corronary insufficiency, arrhythmias resistant to other treatments, wolf parkinson white syndrome.amiodacore intravenous can be used where a rapid response is required or where oral administration is not possible.

Israel - engelsk - Ministry of Health

sanofi israel ltd - alirocumab - solution for injection - alirocumab 150 mg / 1 ml - alirocumab - primary hypercholesterolaemia and mixed dyslipidaemiapraluent is indicated in adults with primary hypercholesterolaemia (heterozygous familial and non-familial) or mixed dyslipidaemia, as an adjunct to diet:- in combination with a statin or statin with other lipid lowering therapies in patients unable to reach ldl-c goals with the maximum tolerated dose of a statin or,- alone or in combination with other lipid-lowering therapies in patients who are statin-intolerant, or for whom a statin is contraindicated.established atherosclerotic cardiovascular diseasepraluent is indicated in adults with established atherosclerotic cardiovascular disease to reduce cardiovascular risk by lowering ldl-c levels, as an adjunct to correction of other risk factors:- in combination with the maximum tolerated dose of a statin with or without other lipid-lowering therapies or,- alone or in combination with other lipid-lowering therapies in patients who are statin-intolerant, or for whom a statin is contraindicated.

Israel - engelsk - Ministry of Health

sanofi israel ltd - alirocumab - solution for injection - alirocumab 75 mg / 1 ml - alirocumab - primary hypercholesterolaemia and mixed dyslipidaemiapraluent is indicated in adults with primary hypercholesterolaemia (heterozygous familial and non-familial) or mixed dyslipidaemia, as an adjunct to diet:- in combination with a statin or statin with other lipid lowering therapies in patients unable to reach ldl-c goals with the maximum tolerated dose of a statin or,- alone or in combination with other lipid-lowering therapies in patients who are statin-intolerant, or for whom a statin is contraindicated.established atherosclerotic cardiovascular diseasepraluent is indicated in adults with established atherosclerotic cardiovascular disease to reduce cardiovascular risk by lowering ldl-c levels, as an adjunct to correction of other risk factors:- in combination with the maximum tolerated dose of a statin with or without other lipid-lowering therapies or,- alone or in combination with other lipid-lowering therapies in patients who are statin-intolerant, or for whom a statin is contraindicated.

Israel - engelsk - Ministry of Health

sanofi - aventis israel ltd - aluminium hydroxide; magnesium hydroxide - suspension - aluminium hydroxide 175 mg / 5 ml; magnesium hydroxide 200 mg / 5 ml - ordinary salt combinations - ordinary salt combinations - antacid.

Israel - engelsk - Ministry of Health

sanofi - aventis israel ltd - danazol - capsules - danazol 200 mg - danazol - treatment of endometriosis amenable to hormonal management, hereditary angioedema.

Israel - engelsk - Ministry of Health

sanofi israel ltd - laronidase - concentrate for solution for infusion - laronidase 500 units / 5 ml - laronidase - laronidase - aldurazyme is indicated for long-term enzyme replacement therapy in patients with a confirmed diagnosis of mucopolysaccharidosis i (mps i alfa-l-iduronidase deficiency) to treat the non-neurological manifestations of the disease.

Israel - engelsk - Ministry of Health

sanofi israel ltd - riluzole - film coated tablets - riluzole 50 mg - riluzole - riluzole - rilutek is indicated to extend life or the time to mechanical ventilation for patients with amyotrophic lateral sclerosis (als).